Status:
RECRUITING
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Solid Tumor Malignancies
Metastatic Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is a hybrid decentralized, single-arm, interventional study designed to evaluate the impact of precision medicine navigation and reflexive expert review of next-generation sequencing (NGS) for pa...
Detailed Description
Despite data supporting a survival benefit in many cancers, rates of NGS testing and subsequent GIT are reported to be low in real-world data sets. Rates of multigene panel-based testing and targeted ...
Eligibility Criteria
Inclusion
- In order to participate in this study a subject must meet all of the eligibility criteria outlined below.
- Inclusion Criteria
- Written informed consent was obtained to participate in the study and HIPAA authorization for release of personal health information.
- Subjects are willing and able to comply with study procedures based on the judgment of the investigator.
- Age ≥ 18 years at the time of consent.
- ECOG or Karnofsky Performance Status of 0-2.
- Documented Stage IV solid tumor malignancy: NSCLC, CRC, Breast or Bladder Cancer
- The treating provider deems Next Generation Sequencing (NGS) testing appropriate and plans to consider results in either first- or second-line therapy in the metastatic setting
- A genomic tumor test has not been ordered or has been ordered but not resulted.
- Exclusion Criteria:
- • Subjects with an active concurrent malignancy.
Exclusion
Key Trial Info
Start Date :
June 27 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2028
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06896162
Start Date
June 27 2025
End Date
June 1 2028
Last Update
July 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lineberger Comprehensive Cancer Center, University of North Carolina
Chapel Hill, North Carolina, United States, 27599